Modern aspects of diagnostics and treatment of nonsteroid gastropathies in patients with osteoarthrosis by Fediv, O.I. et al.
  
Міністерство охорони здоров’я України 






Український науково-практичний журнал 









головний редактор В.П.Пішак, 
Ю.Т.Ахтемійчук, Л.О.Безруков, О.І.Волошин, І.І.Заморський,  
О.І.Іващук (перший заступник редактора), Т.О.Ілащук, 
А.Г.Іфтодій, І.Ф.Мещишен, В.П.Польовий, 
Р.В.Сенютович, І.Й.Сидорчук,  
В.К.Тащук (відповідальний секретар), С.С.Ткачук 
О.І.Федів (відповідальний секретар), Г.І.Ходоровський 
Наукові рецензенти:  




Чернівці: БДМУ, 2009 




Ю.В.Вороненко (Київ), А.І.Гоженко (Одеса),  
Г.В.Дзяк (Дніпропетровськ), В.М.Єльський (Донецьк), 
В.М.Запорожан (Одеса), В.М.Коваленко (Київ),  
Л.Я.Ковальчук (Тернопіль), І.Р.Кулмагамбетов (Караганда), 
В.М.Князевич (Київ), Є.М.Нейко (Івано-Франківськ),  
С.П.Польова (Чернівці), Ю.П.Спіженко (Київ), В.П.Черних (Харків) 
 
Видається згідно з постановою вченої ради Буковинського державного  
медичного університету (протокол № 9 від 28 травня 2009 року) 
Буковинський медичний вісник 
(Бук. мед. вісник) –  
науково-практичний журнал,  
що рецензується 
Bukovinian Medical Herald 
(Buk. Med. Herald)  
Постановою президії ВАКу України  
від 9 червня 1999 року №1–05/7 
"Буковинський медичний вісник" 
включено до переліку видань, в яких 
можуть публікуватися основні ре-
зультати дисертаційних робіт  
Заснований у лютому 1997 р.  
Видається 4 рази на рік 
 
Founded in February, 1997 
Published four times annually 
 
Мова видання: українська,  
російська, англійська 
 
Сфера розповсюдження  
загальнодержавна, зарубіжна 
 
Свідоцтво про державну  
реєстрацію: серія КВ №2375  
від 14.02.1997  
Адреса редакції: 58000, Чернівці,  
пл. Театральна, 2 
 
Тел.: (0372) 55-37-54, 54-36-61,  
52-40-78, 52-65-59 
Факс: (0372) 55-37-54 
e-mail: bmv@bsmu.edu.ua 
 
Адреса електронної версії  
журналу в Internet: 
http://www.bsmu.edu.ua 
 
Секретар редакції  
І.І.Павлуник 
Тел.: (0372) 52-40-78  
© Буковинський медичний вісник, 2009 
 109 
Буковинський медичний вісник         Том 13, №2, 2009 
 
Abstract. A bibliographical review deals with mod-
ern data, concerning the diagnosis and treatment of gas-
tropathies induced by nonsteroidal anti-inflammatory drugs 
in patients with osteoarthrosis. 
Key words: nonsteroidal gastropathies, diagnosis, 
treatment.  
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MODERN ASPECTS OF DIAGNOSTICS AND TREATMENT OF NONSTEROID 
GASTROPATHIES IN PATIENTS WITH OSTEOARTHROSIS 
Department of Internal Medicine and Endocrinology (Head – Prof. O.I. Fediv)  
of Bukovinian State Medical University, Chernivtsi 
Osteoarthrosis (OA) is an important medico-
social problem that results in temporary disability, 
invalidism and an essential decline of patients’ qual-
ity of life. In Ukraine OA is detected in 47,7 % of 
women aged 40-49 years, in 62,8 % – 50-59 years of 
age, in 74,9 % – 60-69 years of age, in 79,9 % – 
older than 65 years. These indices in men make up 
respectively 56,6 %; 72,3 %; 83,7 % and 88,6 % 
[13]. OA makes up 60 % within the framework of 
the disease incidence and according to the findings 
of the state statistics its prevalence constituted 
2351,9 per 100 thousand of the population in 2002. 
The pathology in question ranks second and third as 
far as the disease incidence is concerned after coro-
nary disease and cerebrovascular disease in persons 
aged 45-59 years in the countries of Europe [19]. In 
the USA OA of the knee joints occurs in about 6 % 
of residents over 30 years of age, whereas that of the 
coxal joint – in 3 % [9]. Up to 2020 an increase of 
the disease incidence is expected by 57 % according 
to forecasts of specialists, whereas cases with a re-
stricted activity associated with this disease – up to 
66 % [5]. By now nonsteroidal anti-inflammatory 
drugs (NSAIDs) make up the basis of OA treatment. 
This particular group of drugs has a broad spectrum 
of the curative effect, uniquely combining the antiin-
flammatory, analgesic, antifebrile and antithrombotic 
effects, they influence on the processes of neogene-
sis, cell adhesion and apoptosis. Just because of that 
NSAIDs are the most widely used preparations in 
medicine. Annually 500 million prescriptions for 
these drugs are written out, around 30 million people 
take them daily, 2/3 of the patients – without a pre-
scription and doctor’s supervision [7]. However, 
along with the curative effect NSAIDs exert a toxic 
action on the alimentary canal (AC), liver, central 
nervous system, cardio-vascular and respiratory sys-
tem, the renal filtration activity, teratogenecity and 
embryotoxisity. According to bibliographical find-
ings 46,5 % of side effects in Ukraine are due to 
NSAIDs [7]. The curative and side aspects are pro-
vided by the pathogenetic mechanism of suppressing 
the activity of the enzyme of cyclooxygenase (COX), 
in the metabolism of the arachidonic acid, as a result 
of which the synthesis of prostaglandins (PGs) is 
reduced. Two isoforms of cyclooxygenase have been 
revealed by now – COX-1 and COX-2. The COX-1 
enzyme is permanently present in the AC, kidneys, 
thrombocytes and insures the synthesis of thrombox-
ane A2, PG E2 and prostacyclin that perform a cyto-
protective action. COX-2 in health exists in a small 
amount in the brain and kidneys, it is detected in 
other tissues only in case of a pathological process 
and it induces the synthesis of PGs which participate 
in an inflammation, cellular proliferation and de-
struction. The level of COX-2 is regulated by cyto-
kines, the growth factors and factors that induce tu-
mor growth [4]. There is bibliographical evidence of 
the existence of the 3d isoform – COX-3 which is a 
derivative of COX-1, when it is inhibited there oc-
curs a decrease of the content of prostaglandin E2 
which exerts an antipyretic and analgesic action [1]. 
In addition, the antiinflammatory and analgesic ac-
tions of NSAIDs are associated with a suppression of 
the activation and chemotaxis of neutrophilic granu-
locytes and a diminished production of toxic free 
radicals in activated neutrophilic granulocytes. 
NSAIDs also inhibit the stimulation of monoxide 
nitrogen. Via inhibiting the synthesis of prostagland-
ins NSAIDs influence on apoptosis and enable to 
normalize the life cycle of cells in the focus of in-
flammation [4]. Just the ability of NSAIDs to inhibit 
the functional activity of COX-2 insures a therapeu-
tic action, but simultaneously they also reduce the 
activity of COX-1, bringing about concurrent reac-
tions. On the other hand, a physiological role of 
COX-2 that induced the synthesis of PGs participa-
tion in the regulation of ovulation, the renal and 
cardio-vascular function, a reparation of fractured 
skeletal bones has been established [14]. However, 
even a short-term intake of NSAIDs may result in 
the development of severe complications, on the part 
of the AC, above all. About 20 % of all gastric ulcers 
and 10 % of duodenal ulcers are associated with 
NSAIDs intake, more than half of them being com-
plicated by bleeding and perforation [18]. Some au-
thors believe that the use of NSAIDs in the treatment 
is directly proportional to the frequency of the onset 
of hemorrhages from the upper portions of the gas-
trointestinal tract (GIT). The specific characteristics 
of these erosions and ulcers are their multiple charac-
ter, an asymptomatic or scantily symptomatic course, 
the most frequent localization is in the antral portion 
of the stomach, a high risk of the onset of bleeding, 
the absence of an inflammatory swelling around the 
ulcer, foveolar hyperplasia of the mucous tunic, a 
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rapid repair upon NSAIDs withdrawal [15]. In 1986 
S. Roth suggested a term “NSAID-gastropathy” in 
order to determine injuries of the stomach due to the 
intake of this group of agents. 
Two mechanisms of an immediate and mediated 
effect of NSAIDs are singled out in the pathogenesis 
of an injurious effect on the mucous coat of the 
stomach and the duodenum. A direct injury of the 
AC mucous coat is inflicted by NSAIDs which mani-
fest themselves as weak organic acids that are to be 
found in a nonionized form in the acidic medium of 
the stomach, therefore they act directly on the super-
ficial epithelium, destruct it, enhance permeability of 
hydrogen ions and favour their excessive retrodiffu-
sion. An acute injury of the stomach arises already in 
a few hours in the form of submucous hemorrhages 
and erosions following NSAIDs ingestion. Further 
NSAIDs intake results in a healing of surface ero-
sions in the majority of cases that is accounted for in 
the literature by the phenomenon of adaptation to the 
drug action. The mediated action of NSAIDs on the 
mucous coat is provided via a sharp inhibition of the 
activity of COX-1, as a result of which the activity of 
PGs, insuring the cytoprotection of the mucous coat 
of the stomach, decreases. PG I2 deficiency leads to 
an impaired blood flow in the wall of the stomach, 
disturbed stabilization of the membranes of the mast 
cells of lysosomes, an elevated production of oxygen 
radicals and enzymes by neutrophils, an impaired 
regulation of the vascular endothelium. A reduction 
of PG E2 is conducive to a decrease of the secretion 
of bicarbonates and gastric mucus in consequence of 
which an increase of the gastric secretion ensues. 
NSAIDs are also capable of switching the metabo-
lism of the arachidonic acid from the prostaglandin 
pathway to the lypoxygenase pathway and promoting 
the synthesis of leukotrienes that exert a toxic effect 
on the AC and induce the development of a local 
inflammation at the expense of the adhesion of neu-
trophils to the endothelium [6, 15]. On inhibiting 
COX-1 thrombocyte aggregation is also impaired, 
accounting for an increased risk of gastrointestinal 
hemorrhages [8]. A great role in the pathogenesis of 
NSAID-gastropathies is played by nitric oxide (NO) 
which maintains the gastrointestinal blood circula-
tion, inhibiting the adhesion and activation of neutro-
phils, captures free radicals, prevents leukocyte ad-
hesion to the vascular wall and an injury of the stom-
ach in hemorrhagic shock. An inhibition of its pro-
duction results in a deteriorated condition of the mu-
cous coat of the stomach and duodenum, stimulates 
the adhesion of leukocytes to the vascular epithelium 
and a blood flow disturbance of the AC. It has a di-
rect effect on the secretory properties of the stomach, 
on the properties of its mucous coat to interfere with 
the action of the aggression factors, on the onset and 
healing of erosions and ulcers [6]. As a result of 
proving the physiological role of nitric oxide in the 
AC modified NSAIDs have been created, containing 
the sources of nitric oxide that point out their antiul-
cerous activity [2]. A change of lipid peroxidation 
(LPO) plays a certain role in the mechanism of the 
ulcerogenic action of NSAIDs. The products of lipid 
free radical oxidation, forming as a result of the toxic 
effect of NSAIDs, participate in damaging the mu-
cous coat of the stomach, as well as in ruining muco-
polysaccharides. The activation of POL is regarded 
by many researchers as a leading mechanism of the 
development of erosive – ulcerous damages of the 
stomach and duodenum and as a side effect of treat-
ing with NSAIDs. 
G.Yetkin et al. [33] mark a protective impact of the 
transforming growth factor-α (TGF-α) on the AC mucous 
coat in case of ulcers induced by NSAIDs. TGF-a intensi-
fies the healing of the ulcerous defect [22]. 
The problem of an association of Helicobacter 
pylori (Hp) and AC pathology caused by the intake of 
NSAIDs has not been cleared up to the end up till now. 
It is known that Hp may protect the upper parts of the 
AC by means of elevating the level of prostaglandins, 
however, clinical studies of this question indicate that 
the elimination of Hp leads to a diminished risk of pa-
thology of the stomach and duodenum in persons who 
are treated with NSAIDs and a combination of a pro-
longed ingestion of NSAIDs and Hp essentially en-
hances the risk of hemorrhages [20]. There are biblio-
graphical findings pertaining to an intensification of 
apoptosis of the epithelial cells of the stomach in pa-
tients with Hp who take NSAIDs and a decrease of this 
index following Hp eradication that may be indicative 
of a synergic action of the AC damage [26]. 
Some investigators consider that Hp and 
NSAIDs exert an influence on the mucous coat of 
the stomach independently of each other and do not 
enhance the action of one another [27]. It is noted in 
the Maasstricht concensus 2- 2000 that the eradica-
tion of Hp lowers the risk of new ulcers in the pres-
ence of already existing ones in patients whose an-
amnesis includes a prolonged treatment with 
NSAIDs. According to the findings of the concensus 
of Maasstricht-2003 the correlation between Hp and 
NSAIDs is complex, almost all peptic ulcers are as-
sociated with these two factors, they are independent 
factors of the incipience of both peptic ulcers and 
ulcerous bleedings. 
The management of NSAIDs-gastroduodeno-
pathies in patients with osteoporosis is rather a com-
plicated and topical problem, so long as the cessation 
of NSAID therapy as the principal cause of the oc-
currence of gastroduodenopathies in these patients is 
impossible on account of an exacerbation of the un-
derlying disease. Having studied the mechanisms of 
the adverse reaction of NSAIDs, new approaches to 
the treatment of gastric and duodenal lesions under 
the influence of these drugs have been elaborated. 
During the period from 1990 through 2000 new 
NSAIDs – selective COX-2 inhibitors were intro-
duced into medical practice. They don’t differ from 
the classical NSAIDs as far as efficacy is concerned, 
but they are almost free of side effects on the part of 
the AC. Large-scale numerous trials (VIGOR, 
CLASS and others) note a lower rate of erosive-
ulcerous lesions and their complications, while tak-
ing selective COX-2 inhibitors compared to those 
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observed, while taking traditional NSAIDs. The 
same findings were obtained by many other re-
searchers [29, 30]. In accordance with the NISE rec-
ommendations of 2001 selective NSAIDs are pre-
scribed if risk factors of NSAIDs-induced gas-
tropathies are available. In 2001 it was confirmed by 
FDA that the risk of the onset of erosive-ulcerous 
lesions of the stomach and duodenum preserved, 
when using selective COX-2 inhibitors as well. 
Some authors believe that selective NSAIDs cause 
gastric and duodenal ulcers 3-4 times less seldom, as 
well as lesions of the small intestine [11]. C.I.Haw-
key et al. point out that selective COX-2 inhibitors, 
likewise nonselective ones, cause the same danger-
ous side effects under the action of two and more 
risk factors [24]. Nowadays, the central place among 
medical agents used for the treatment of gastroduo-
denopathies induced by NSAIDs is occupied by pro-
ton pump inhibitors (PPIs) [21]. On the basis of 
some experimental findings (ASTRONAUT, OM-
NIUM, SCUR, OPPULENT) PPIs are more effective 
than other drugs in exerting a protective effect on the 
mucous coat of the gastrointestinal tract (GIT), pre-
venting its damage and contributing to a rapid heal-
ing of ulcers and erosions following the intake of 
NSAIDs [10, 17]. An additional prescription of safe 
PPIs suppresses the acid production, they don’t enter 
into competitive interdrug interactions with NSAIDs 
that is regarded to be the basis of preventing and 
treating NSAIDs-associated gastroduodenopathies, 
particularly, active gastric ulcers [15]. J.Greenberg’s 
studies showed that in 2005 following “coxib crisis” 
selective NSAIDs are taken by 36,1 % of patients, 
whereas PPIs – 53,7 %. This ratio makes up 37,2 % 
and 57,1 % among patients without risk factors, with 
one risk factor – 37,2 % and 57,1 %, with two and 
more risk factors – 41,5 % and 65,4 % respectively 
[23]. An analysis of the results of 32 researches, 
studying the efficacy of PPIs in the treatment of pep-
tic ulcer and gastroesophageal disease, has demon-
strated that, regardless of some distinctions among 
PPIs, there are no data in favour of one PPI having 
greater efficacy compared to others [31]. As to the 
use of H2-blockers in standard doses to prevent the 
development and relapses of gastric ulcers and ero-
sions they are not effective, however, they reliably 
lower the risk of the development of duodenal pa-
thology, whereas high doses may be used to prevent 
NSAIDs-induced gastric ulcers [12]. Trials were 
carried out in Japan among patients who took 
NSAIDs protractedly and where the prophylactic 
efficacy of the intake of PPIs, H2-blockers and miso-
prostol was evaluated. The rate of the origin was 
essentially lower, when using H2-blockers [28]. 
There is bibliographical evidence to the effect that 
misoprostol (a synthetic analog of prostaglandin E2) 
endowed with cytoprotective properties in relation to 
the gastrointestinal mucous membrane and in combi-
nation with nonselective NSAIDs reduces the rate of 
the development of gastric and duodenal ulcers, as 
well as the risk of the onset of ulcerous complica-
tions, at least half as much [11]. This medication 
suppresses the acid and pepsin production by the 
stomach, increases the amount of mucus and the den-
sity of the mucous gel, elevates the release of bicar-
bonates and improves the blood circulation in the 
gastric mucosa, favours the restoration of the cells of 
the mucous coat and diminishes a reverse diffusion 
of hydrogen ions. It may be used for the treatment of 
NSAID-gastropathies, but the bulk of investigations 
are devoted to its prophylactic action. In the trials of 
OMNIUM in which misoprostol was administered to 
125 patients with gastric ulcers 60 – with duodenal 
ulcers and 97 – with multiple ulcers, a healing of the 
ulcers was noted in 62 %, 61 % and 75 % in 4 
weeks, whereas in 8 weeks – in 72 %, 77 % and 
87 % of patients respectively [10]. However, it is not 
advisable to take misoprostol combined with antac-
ids, since they reduce essentially its plasma concen-
tration [3]. The American Association of Gastroen-
terologists has recommended to use misoprostol in 
the treatment of patients with ulcerous anamnesis 
who take NSAIDs together with anticoagulants or 
glucocorticoids, or they have concomitant severe 
diseases [6]. Some researchers point out that nowa-
days American doctors prescribe misoprostol consid-
erably less frequently and give preference to PPIs 
[21, 25]. A promising prospect for a successful treat-
ment is creating drugs enriched with NO that pro-
tects the mucous coat from the damaging action [32]. 
Of late in order to treat and prevent NSAIDs-
induced gastropathies they have started to use a new 
preparation Rebamipid (“Mucogen”, Macleods Phar-
maceuticals Limited), which elevates the content of 
endogenous PG E2 and I2 in the mucous coat of the 
stomach and therethrough raises the regenerative 
properties of the gastric mucosa, insures its protec-
tion from damaging factors. Mucogen stimulates the 
secretion of bicarbonates to maintain the pH gradi-
ent, improves the blood circulation in the mucous 
coat and intensifies cell proliferation. The amount of 
the superficial gastric mucus under the influence of 
treating with Rebamipid increases by 160 %. Muco-
gen also inhibits the migration and activation of neu-
trophils, diminishes the adhesion of Hp to the gastric 
mucosa and does not influence on the basal and 
stimulated gastric secretion of the hydrochloric acid. 
Mucogen is used to prevent the development of recur-
rences following the treatment of erosive-ulcerous 
lesions of the gastric mucosa and duodenum by form-
ing a flat scar with diminished remodelling of the 
gastric wall, a normalization of the microcirculation 
and a restoration of adequate epithelization [16]. 
Thus, the question of gastropathies induced by 
nonsteroidal anti-inflammatory drugs in patients with 
osteoarthrosis continues to remain one of the most 
pressing problems of gastroenterology. A promising 
perspective is further in-depth research of the patho-
genetic specific features of gastroduodenopathies 
induced by NSAIDs in patients with osteoarthrosis 
via studying the mechanisms of dysadaptation of the 
mucous coat of the stomach and duodenum. 




1. Бабак О.Я. Применение нестероидных проти-
вовоспалительных средств в терапии / О.Я.Ба-
бак, И.И.Князькова, И.А.Нестерцова // Укр. 
терапевт. ж. – 2007. – № 2.– С. 4-11. 
2. Бухтіарова Т.А. Шляхи корекції побічної дії 
нестероїдних протизапальних препаратів / 
Т.А.Бухтіарова, О.Є.Ядловський, Т.В.Шатир-
кіна [та ін.] // Фармацевт. ж. – 2007. – № 1. – 
С. 38-44. 
3. Васильев Ю.В. Нестероидная гастропатия / 
Ю.В.Васильев // Леч. врач. – 2004. – № 7. – С. 6-10. 
4. Викторов А.П. Мелоксикам – перспективы 
сохраняются! / А.П.Викторов // Терапия. – 
2007. – № 7-8. – С. 36-38. 
5. Гужевский И.В. Современные представления 
о патогенезе, диагностике и медикаментозном 
лечении первичного остеоартроза суставов 
нижних конечностей / И.В.Гужевский // Ж. 
практ. лікаря. – 2005. – № 6. – С. 5-13. 
6. Дзяк Г.В. Сучасний погляд на гастропатії, викли-
кані нестероїдними протизапальними препарата-
ми, целекоксиб і стан секреторної функції шлун-
ка / Г.В.Дзяк, Ю.М.Степанов, В.І.Гриценко [та 
ін.] // Сучасна гастроентерол. – 2003. – № 1 (11). – 
С. 4-11. 
7. Добош І.М. Особливості перебігу гастропатій, 
індукованих нестероїдними протизапальними 
препаратами, в осіб похилого віку / І.М.До-
бош, І.В.Чопей, В.П.Гарчар // Мед. транспор-
ту України. – 2006. – № 1. – С. 96-98. 
8. Дроздов В.Н. Гастропатии, вызванные несте-
роидными противовоспалительными препара-
тами:патогенез, профилактика и лечение / 
В.Н.Дроздов // Consilium medicum. – 2005. – 
Т. 7, № 1. – С. 3-6. 
9. Журавская Т. Влияние нестероидных проти-
вовоспалительных препаратов на длитель-
ность временной нетрудоспособности при 
остеоартрозе / Т.Журавская // Врач. – 2005. – 
№ 6. – С. 40-43. 
10. Каратеев А.Е. Лечение и медикаментозная 
профилактика НПВП-гастропатии: основные 
положения / А.Е.Каратеев // Фарматека. – 
2006. – № 6. – С. 37-45. 
11. Минушкин О.Н. Профилактика НПВС-
гастропатий у больных с факторами риска 
желудочно-кишечных повреждений / О.Н.Ми-
нушкин, Л.В.Масловский, В.М.Леонов // Леч. 
врач. – 2006. – № 2. – С. 92-94. 
12. Насонов Е. Нестероидные противовоспалите-
льные препараты: клинические рекомендации 
по использованию / Е.Насонов, А.Каратеев // 
Врач. – 2007. – № 3. – С. 8-14. 
13. Поворознюк В.В. Остеоартроз: нельзя забыть 
о болезни, но можна ею управлять / В.В.Пово-
рознюк // Здоров’я України. – 2007. – № 4. – 
С. 68. 
14. Подплетняя Е.А. Механизмы гастродуодено-
токсичности нестероидных противовоспали-
тельных средств / Е.А.Подплетняя, В.И.Мам-
чур // Ж. Акад. мед. наук України. – 2005. – 
Т. 11, № 1. – С. 47-62. 
15. Ткач С.М. Современные подходы к профилак-
тике и лечению НПВП-гастропатий / 
С.М.Ткач, М.П.Середа // Сучасна гастроенте-
рол. – 2005. – № 3. – С. 66-71. 
16. Федів О.І. Особливості гоєння ерозивно-
виразкових уражень слизової оболонки шлун-
ка та дванадцятипалої кишки під вливом реба-
міпіду / О.І.Федів, В.М.Багрій, В.В.Труш [та 
ін.] // Сучасна гастроентерол. – 2008. – № 3.– 
С. 53-56. 
17. Швец Н.И. Осложнения со стороны пищева-
рительного тракта, обусловленные примене-
нием нестероидных противовоспалительных 
препаратов. Часть 2. Снижение риска разви-
тия и лечение гастропатий / Н.И.Швец, 
Т.М.Бенца // Укр. мед. часопис. – 2004. – № 5 
(43). – С. 75-83. 
18. Щокіна К.Г. Порівняння гастротоксичності су-
часних і перспективних НПЗЗ / К.Г.Щокіна, 
О.П.Вікторов // Ліки. – 2005. – № 3-4. – С. 47-53. 
19. Якименко Е.А. Изучение эффективности и безо-
пасности применения зинаксина в комплексной 
терапии больных с остеоартрозом / 
Е.А.Якименко, Л.В.Закатова, О.Е.Кравчук [и 
др.] // Укр. терапевт. ж. – 2005. – № 1. – С. 64-66. 
20. Fendrick A.M. Helicobacter pylori and NSAID 
gastropathy: an ambiguous association / 
A.M.Fendrick, J.M.Scheiman // Curr. Rheumatol. 
Rep. – 2001. – Vol. 3, № 2. – P. 107-111. 
21. Fries J. The rise and decline of nonsteroidal anti-
inflammatory drug-associated gastropathy in rheuma-
toid arthritis / J.Fries, N.Kristen, M.Bennet [et al.] // 
Arthr. and Rheum. – 2004. – Vol. 50. – P. 2433-2440. 
22. Ganul B. The role of transforming growth factor 
alpha formulation on aspirin-induced ulcer heal-
ing and oxidant stress in the gastric mucosa / 
B.Ganul, K.Akbulut, C.Ozer [at al.] // Surg. To-
day. – 2004. – Vol. 34, № 12. – P. 1035-1040. 
23. Greenberg J. Decline of NSAID gastroprotection in 
patients treated by rheumatologist in the post-
rofecoxib era / J.Greenberg, Y.Yariei, J.Kremer [et 
al.] // Arthritis Rheum. – 2006. – Vol. 54. – P. 109. 
24. Hawkey C.J. Gastrointestinal safety of selective 
COX-2 inhibitors / C.J.Hawkey, M.M.Skelly // 
Curr. Pharm. Des. – 2002. – Vol. 8. – P. 1077-1089. 
25. Lain L. Proton pump inhibitor co-therapy with 
nonsteroidal anti-inflammatory drugs-nice or 
necessery? / L.Lain // Rew. Gastroenterol. Dis. – 
2004. – Vol. 4. – P. 33-41. 
26. Leung W.K. Clarithromycin for Helicobacter 
pylori infection / W.K.Leung, D.Y.Graham // 
Expert. Opin. Pharmacother. – 2000. – Vol. 1, 
№ 3. – P. 507-514. 
27. Prevalence of Helicobacter pylori in NSAID us-
ers with gastric ulcer / Y.Matsukawa, M.Aoki, 
S.Nishinarita [et al.] // Rheumatology. – 2003. – 
Vol. 42. – P. 947-950. 
28. Preventive therapy for non-steroidal anti-
inflammatory drug-induced ulcers in Japanese 
 113 
Буковинський медичний вісник         Том 13, №2, 2009 
 
Рецензент – проф. О.І.Волошин Buk. Med. Herald. – 2009. – Vol.13, №2.–P.109-113 
Надійшла до редакції 21.04.2009 року 
 
patients with rheumatoid arthritis: the current 
situation and a prospective controlled-study of 
the preventive effects of lansoprazole or famo-
tidin / K.Miyake, N.Ueki, K.Suzuki [et al.] // 
Aliment. Pharmacol. Ther. – 2005. – Suppl. 2. – 
P. 67-72. 
29. NSAID and coxib use by the elderly in general 
practice: effect on upper gastrointestinal symp-
toms and therapies / A.Pilotto, M.Franceschi, 
D.Vitale [et al.] // Gut. – 2004. – Vol. 53. – P. 119. 
30. Rachme E. Gastrointestinal effects of rofecoxib 
and celecoxib versus NSAIDS among patients in 
low dose aspirin / E.Rachme, M.Bardou, K.Das-
gupta [et al.] // Gut. – 2004. – Vol. 53. – P. 35. 
31. Vakil N. Systematic review Direct comparative 
trials of the efficacy on proton pump inhibitors in 
the management of gastro esophageal reflux disease 
and peptic ulcer / N.Vakil, M.Fenerty // Aliment. 
Pharmacol. Ther. – 2003. – Vol. 18. – P. 556-558. 
32. Wilder-Smith С. Upper gastrointestinal tract mu-
cosal injury by AZD3582, A coxinhibiting nitric 
oxide donor (cinod) and naproxen: a randomized, 
double-blind, crossover study in healthy sub-
jects / С.Wilder-Smith, J.Robert, D.Schindler // 
Gut. – 2004. – Vol. 53 (suppl. 6). – P. 36. 
33. The healing effect of TGF-alpha on gastric ulcer 
induced by acetylsalicylic acid in rats / G.Yetkin, 
N.Celebri, C.Ozer [et al.] // Int. J. Pharm. – 2004. – 
Vol. 277, № 1-2. – P. 163-172. 
CОВРЕМЕННЫЕ АСПЕКТЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ НЕСТЕРОИДНЫХ  
ГАСТРОПАТИЙ У БОЛЬНЫХ ОСТЕОАРТРОЗОМ 
А.И.Федив, Л.М.Гресько, С.А.Гресько, Р.Р.Бойчук 
Резюме. В обзоре литературы приведены современные данные по диагностике и лечению гастропатий, инду-
цированных нестероидными противовоспалительными препаратами, у больных остеоартрозом. 
Ключевые слова: нестероидные гастропатии, остеоартроз, диагностика, лечение. 
СУЧАСНІ АСПЕКТИ ДІАГНОСТИКИ І ЛІКУВАННЯ НЕСТЕРОЇДНИХ  
ГАСТРОПАТІЙ У ХВОРИХ НА ОСТЕОАРТРОЗ 
О.І.Федів, Л.М.Гресько, С.О.Гресько, Р.Р.Бойчук 
Резюме. В огляді літератури наведені сучасні дані щодо діагностики і лікування гастропатій, індукованих 
нестероїдними протизапальними препаратами, у хворих на остеоартроз. 
Ключові слова: нестероїдні гастропатії, остеоартроз, діагностика, лікування. 
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